Search research articles
Contact Us
Filters
Showing results (81-90 of 95) with videos related to
Page
of 10
Sort By:
Pediatric Blood & Cancer
|
August 19, 2025
Neuroblastoma in Infants: Long-Term Survival From INES Protocols A SIOPEN Study
Julie Savagner, Caroline Munzer, Gudrun Schleiermacher, et al.
Clinical Genetics
|
February 15, 2021
Immune deficiency, autoimmune disease and intellectual disability: A pleiotropic disorder caused by biallelic variants in the TPP2 gene
Isis Atallah, Mathieu Quinodoz, Belinda Campos-Xavier, et al.
Cancers
|
May 25, 2024
MR Imaging of Adverse Effects and Ocular Growth Decline after Selective Intra-Arterial Chemotherapy for Retinoblastoma
Christiaan M de Bloeme, Sabien van Elst, Paolo Galluzzi, et al.
Cancers
|
February 5, 2020
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.
The Lancet. Oncology
|
November 17, 2018
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.
The Lancet. Oncology
|
March 6, 2017
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial
Ruth Ladenstein, Ulrike Pötschger, Andrew D J Pearson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2026
Current treatment strategies for first relapse of high-risk neuroblastoma
Sveva Castelli, Franziska Schulze, Theresa M Thole-Kliesch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 9, 2020
Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study
Keith Holmes, Ulrike Pötschger, Andrew D J Pearson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2020
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable <i>MYCN</i>-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group
Inge M Ambros, Gian-Paolo Tonini, Ulrike Pötschger, et al.
Pediatric Blood & Cancer
|
March 15, 2021
Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG)
Sabine Dittner-Moormann, Madlen Reschke, Floor C H Abbink, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 95) with videos related to
Sort By:
Page
of 10
Pediatric Blood & Cancer
|
August 19, 2025
Neuroblastoma in Infants: Long-Term Survival From INES Protocols A SIOPEN Study
Julie Savagner, Caroline Munzer, Gudrun Schleiermacher, et al.
Clinical Genetics
|
February 15, 2021
Immune deficiency, autoimmune disease and intellectual disability: A pleiotropic disorder caused by biallelic variants in the TPP2 gene
Isis Atallah, Mathieu Quinodoz, Belinda Campos-Xavier, et al.
Cancers
|
May 25, 2024
MR Imaging of Adverse Effects and Ocular Growth Decline after Selective Intra-Arterial Chemotherapy for Retinoblastoma
Christiaan M de Bloeme, Sabien van Elst, Paolo Galluzzi, et al.
Cancers
|
February 5, 2020
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.
The Lancet. Oncology
|
November 17, 2018
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.
The Lancet. Oncology
|
March 6, 2017
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial
Ruth Ladenstein, Ulrike Pötschger, Andrew D J Pearson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2026
Current treatment strategies for first relapse of high-risk neuroblastoma
Sveva Castelli, Franziska Schulze, Theresa M Thole-Kliesch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 9, 2020
Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study
Keith Holmes, Ulrike Pötschger, Andrew D J Pearson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2020
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable <i>MYCN</i>-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group
Inge M Ambros, Gian-Paolo Tonini, Ulrike Pötschger, et al.
Pediatric Blood & Cancer
|
March 15, 2021
Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG)
Sabine Dittner-Moormann, Madlen Reschke, Floor C H Abbink, et al.
Page
of 10